Indian startup PredOmix has developed an AI-based blood test for early cancer detection with a reported accuracy rate of 98 percent. PredOmix’s patented OncoVeryx-F technology combines metabolomics and Artificial Intelligence (AI) to recognize metabolic signatures of multiple cancers in one test. With this technology, it can detect 32 cancers that are especially difficult to detect for both men and women, including breast cancer, bladder cancer, and prostate cancer. The company has conducted trials that collected blood samples from 4,000 people in various locations from India, with a successful detection accuracy rate of 98 percent. Moreover, PredOmix has launched clinical trials with over 10,000 participants in India, and is planning to get a Drug Control General of India (DCGI) approval in the near future.
The company is co-founded and headed by Dr. Kanury V.S. Rao, a scientist who is pioneering this novel method of cancer detection. His research, which consists of metabolomics and the effective use of big data algorithms, is integral in extracting cancer biomarkers from serum samples accurately. Dr. Rao firmly believes that earlier detection of the disease can improve survival overall and reduce mortality throughout the world. As a result, this advanced AI-based technology presents an effective and modern way of combating cancer mortality.
Apart from embracing new technologies, the Indian government is also playing a terrific role in digitization and growth. Many applications such as AarogyaSetu and UMANG are designed to help the Indian population acquire digital literacy in the country, helping to spread education, health awareness and valuable resources.
Overall, AI-based novel cancer testing works towards detecting cancer early and improving treatment outcomes leading to a higher survival rate. Through its universal applicability, PredOmix has made a significant contribution towards improving the access of basic medical care, a crucial part of modern healthcare.
